Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IVRA vs IBU
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.
Onchocerciasis (river blindness),Strongyloidiasis (threadworm infection),Scabies (off-label, FDA-approved for scabies in certain contexts; also used off-label for head lice, pediculosis, and various parasitic infections)
Rheumatoid arthritis,Osteoarthritis,Mild to moderate pain,Dysmenorrhea,Fever,Patent ductus arteriosus closure in neonates (off-label)
Intravenous 500 mg every 6 hours.
200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.
Terminal elimination half-life is approximately 12-15 hours in healthy adults; prolonged in hepatic impairment (up to 30 hours) and in elderly patients.
Terminal elimination half-life: 2-4 hours in adults; prolonged in neonates (30 hours) and elderly (up to 6 hours). No accumulation with recommended dosing due to short t½.
Primarily metabolized by CYP3A4 in the liver; also a substrate for P-glycoprotein (P-gp) transporter.
Hepatic metabolism primarily via CYP2C9 to inactive metabolites; minor pathways include CYP2C8.
Renal excretion of unchanged drug accounts for approximately 10-20% of elimination; fecal/biliary excretion is the primary route (60-70% as metabolites, primarily unchanged drug via bile).
Renal (90% as conjugated metabolites, 10% unchanged), biliary/fecal (minor, <5%)
Approximately 85-90% bound to plasma proteins, primarily albumin and alpha-1-acid glycoprotein.
99% bound primarily to albumin
0.6-0.8 L/kg, indicating distribution into total body water with some extravascular binding; increased in heart failure or severe hepatic disease.
0.1-0.2 L/kg, indicating low tissue distribution; predominantly confined to plasma and extracellular fluid.
Oral: 70-80% (extensive first-pass metabolism reduces from 90% absorbed); Intravenous: 100%.
Oral: 80-100% (immediate-release), 70-90% (extended-release); Topical: approximately 5-10% systemic absorption; Intravenous: 100%.
GFR >60 m L/min: 500 mg q6h; GFR 30-60: 250 mg q6h; GFR 15-30: 250 mg q12h; GFR <15: 250 mg q24h.
Cr Cl >30 m L/min: no adjustment. Cr Cl 10-30 m L/min: 200 mg every 12 hours; avoid if Cr Cl <10 m L/min.
Child-Pugh A: no adjustment; Child-Pugh B: 250 mg q6h; Child-Pugh C: 250 mg q12h.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% or avoid. Child-Pugh C: contraindicated due to risk of hepatotoxicity.
10 mg/kg IV every 6 hours; maximum 500 mg per dose.
6 months to 12 years: 5-10 mg/kg/dose every 6-8 hours; max 40 mg/kg/day. For juvenile idiopathic arthritis: 30-40 mg/kg/day divided every 6-8 hours; max 50 mg/kg/day.
Same as adult; monitor renal function and adjust per GFR.
Initiate at lowest effective dose; consider 200 mg every 8-12 hours; monitor renal function and GI bleeding risk.
None.
NSAIDs cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. Risk may increase with duration of use. Contraindicated for treatment of peri-operative pain in coronary artery bypass graft (CABG) surgery.
Potential for severe adverse reactions (Mazzotti reaction) in onchocerciasis patients; neurotoxicity (especially in elderly or patients with high drug levels); avoid use in patients with impaired hepatic function; caution with concomitant use of CNS depressants; not recommended in pregnancy (Category C).
Cardiovascular thrombotic events,Gastrointestinal bleeding, ulceration, and perforation,Hypertension,Heart failure exacerbation,Renal toxicity,Anaphylactic reactions,Serious skin reactions (e.g., Stevens-Johnson syndrome),Hematologic effects (anemia, bleeding)
Hypersensitivity to ivermectin or any component of the formulation; not for use in pediatric patients weighing less than 15 kg for scabies treatment (due to risk of neurotoxicity).
History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Peri-operative pain in CABG surgery,Active gastrointestinal bleeding,Advanced renal disease,Third trimester of pregnancy
No food interactions with IVRA technique; however, lidocaine administration may be affected by grapefruit juice (inhibits metabolism) — avoid grapefruit juice before procedure.
Ibuprofen can increase the risk of stomach bleeding when taken with alcohol. No specific food restrictions, but taking with food or milk can reduce GI irritation.
IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal nephrotoxicity, oligohydramnios, and premature ductus arteriosus closure.
First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of premature closure of ductus arteriosus, oligohydramnios, and neonatal renal impairment; contraindicated after 30 weeks gestation.
Excreted into breast milk in low amounts; M/P ratio 0.3. Avoid use due to potential adverse effects in nursing infants (renal impairment, bleeding).
Ibuprofen is excreted into breast milk in low concentrations (M/P ratio approximately 0.01-0.03). Considered compatible with breastfeeding by the American Academy of Pediatrics; use lowest effective dose for shortest duration.
No dose adjustment is recommended as IVRA is contraindicated. In case of inadvertent use in pregnancy, discontinue immediately.
Increased plasma volume and renal clearance in pregnancy may reduce drug levels; however, no standard dose adjustment recommended. Use lowest effective dose, avoid in third trimester.
IVRA (intravenous regional anesthesia) is not a drug but a technique. For Bier block using lidocaine, use 0.5% preservative-free lidocaine, 3 mg/kg for upper extremity. Avoid in patients with sickle cell disease or severe hypertension. Monitor for tourniquet pain after 30 minutes; deflate tourniquet gradually to prevent systemic toxicity.
Ibuprofen is a nonselective COX inhibitor with anti-inflammatory, analgesic, and antipyretic effects. Avoid in patients with aspirin allergy, active peptic ulcer, or severe renal impairment. Use lowest effective dose for shortest duration to minimize GI and cardiovascular risks. Not recommended in patients with advanced chronic kidney disease (e GFR <30 m L/min/1.73 m²). For acute pain, ibuprofen 200-400 mg every 6 hours PRN. Monitor for signs of GI bleeding, hypertension, and fluid retention.
You will receive local anesthetic injected into a vein in your arm after a tourniquet is applied.,The tourniquet will be kept inflated during the procedure to keep the medication in the arm.,You may feel a burning sensation when the medication is injected, which is normal.,Do not remove the tourniquet yourself; it will be deflated slowly by the doctor to prevent side effects.,Report any chest discomfort, ringing in ears, or metallic taste immediately.
Take with food or milk to reduce stomach upset.,Do not exceed 1200 mg per day unless directed by your doctor.,Avoid alcohol while taking this medication.,Stop use and seek medical help if you experience chest pain, weakness, slurred speech, or signs of stomach bleeding (black/tarry stools, vomit that looks like coffee grounds).,Do not take with other NSAIDs or aspirin without consulting your healthcare provider.
No interactions on record
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IVRA vs IBU, answered by our medical review team.
IVRA is a Nonsteroidal Anti-Inflammatory Drug (NSAID) that works by Ivermectin binds selectively and with high affinity to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased chloride ion influx and hyperpolarization, resulting in paralysis and death of the parasite. It also interacts with gamma-aminobutyric acid (GABA)-gated chloride channels.. IBU is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, thereby reducing inflammation, pain, and fever.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IVRA and IBU depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IVRA is: Intravenous 500 mg every 6 hours.. The standard adult dose of IBU is: 200-800 mg orally every 6-8 hours as needed; maximum 3200 mg/day. For OTC use: 200-400 mg every 4-6 hours; max 1200 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IVRA and IBU in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IVRA is classified as Category C. IVRA is contraindicated in pregnancy. First trimester: high risk of major congenital malformations (neural tube defects, cleft palate). Second and third trimesters: risk of fetal n. IBU is classified as Category C. First and second trimester: Increased risk of miscarriage and congenital malformations (particularly cardiac defects) associated with NSAID use. Third trimester: Known risk of prem. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.